Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCP-2201
- Development stage
- Phase 1
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HCP-2201 is a small molecule drug developed by Hanmi Pharmaceutical Co., Ltd. It is currently in clinical development with a focus on evaluating its pharmacokinetic characteristics and safety profile. The exact mechanism of action for HCP-2201 is unknown as of the latest available data. The drug has been studied in phase 1 clinical trials involving healthy male volunteers to assess its pharmacokinetics and safety when administered alone or in combination with other components under fasting conditions. It is administered orally.
- Other names
- HCP-2201HCP2201HCP 2201
Beyond the preview
Go deeper on HCP-2201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCP-2201.